WO2006044958A8 - Derives de pyrazolo[1,5-alpha]pyrimidinyle utiles comme antagonistes vis-a-vis du recepteur du facteur de liberation de la corticotropine (crf) - Google Patents

Derives de pyrazolo[1,5-alpha]pyrimidinyle utiles comme antagonistes vis-a-vis du recepteur du facteur de liberation de la corticotropine (crf)

Info

Publication number
WO2006044958A8
WO2006044958A8 PCT/US2005/037576 US2005037576W WO2006044958A8 WO 2006044958 A8 WO2006044958 A8 WO 2006044958A8 US 2005037576 W US2005037576 W US 2005037576W WO 2006044958 A8 WO2006044958 A8 WO 2006044958A8
Authority
WO
WIPO (PCT)
Prior art keywords
crf
receptor antagonists
corticotropin
pyrazolo
alpha
Prior art date
Application number
PCT/US2005/037576
Other languages
English (en)
Other versions
WO2006044958A1 (fr
Inventor
Marion Lanier
Zhiyong Luo
Manisha Moorjani
John Edward Tellew
John P Williams
Xiaohu Zhang
Original Assignee
Sb Pharmco Inc
Neurocrine Biosciences Inc
Marion Lanier
Zhiyong Luo
Manisha Moorjani
John Edward Tellew
John P Williams
Xiaohu Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006044958(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc, Neurocrine Biosciences Inc, Marion Lanier, Zhiyong Luo, Manisha Moorjani, John Edward Tellew, John P Williams, Xiaohu Zhang filed Critical Sb Pharmco Inc
Priority to CA2584567A priority Critical patent/CA2584567C/fr
Priority to NZ554082A priority patent/NZ554082A/en
Priority to AU2005295353A priority patent/AU2005295353B2/en
Priority to BRPI0517073-7A priority patent/BRPI0517073A/pt
Priority to MX2007004701A priority patent/MX2007004701A/es
Priority to JP2007537996A priority patent/JP4901744B2/ja
Priority to EP05818308A priority patent/EP1802627B1/fr
Priority to US11/576,957 priority patent/US7879862B2/en
Publication of WO2006044958A1 publication Critical patent/WO2006044958A1/fr
Publication of WO2006044958A8 publication Critical patent/WO2006044958A8/fr
Priority to KR1020087007620A priority patent/KR20080063760A/ko
Priority to EP06805979A priority patent/EP1934222B1/fr
Priority to EA200801000A priority patent/EA200801000A1/ru
Priority to JP2008532687A priority patent/JP2009510004A/ja
Priority to CN2006800355977A priority patent/CN101273043B/zh
Priority to CA002624699A priority patent/CA2624699A1/fr
Priority to PCT/EP2006/009531 priority patent/WO2007039264A1/fr
Priority to US12/067,939 priority patent/US8088779B2/en
Priority to BRPI0616767-5A priority patent/BRPI0616767A2/pt
Priority to AU2006298995A priority patent/AU2006298995B2/en
Priority to PE2006001185A priority patent/PE20070845A1/es
Priority to TW095135886A priority patent/TW200745121A/zh
Priority to IL182420A priority patent/IL182420A0/en
Priority to NO20072541A priority patent/NO20072541L/no
Priority to IL190225A priority patent/IL190225A0/en
Priority to MA30813A priority patent/MA29850B1/fr
Priority to NO20081941A priority patent/NO20081941L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des antagonistes vis-à-vis du récepteur CRF pouvant être utiles dans le traitement de divers troubles, y compris le traitement des troubles qui se manifestent par une hypersécrétion du CRF chez les mammifères. Les antagonistes ont la structure ci-après (I). Les antagonistes s'entendent aussi des sels, esters, solvates, stéréoisomères et promédicaments pharmaceutiquement acceptables, et pour les besoins de la formule décrite, R1, R2a, R2b, Y, Het, n, o, R6, Ar et R7 sont tels que définis dans la description. On décrit aussi des compositions qui renferment un antagoniste vis-à-vis du récepteur CRF combinées à un vecteur pharmaceutiquement acceptable, et des procédés d'utilisation correspondants.
PCT/US2005/037576 2004-10-19 2005-10-19 Derives de pyrazolo[1,5-alpha]pyrimidinyle utiles comme antagonistes vis-a-vis du recepteur du facteur de liberation de la corticotropine (crf) WO2006044958A1 (fr)

Priority Applications (25)

Application Number Priority Date Filing Date Title
CA2584567A CA2584567C (fr) 2004-10-19 2005-10-19 Derives de pyrazolo (1,5-alpha)pyrimidinyle utiles comme antagonistes vi-a-vis du recepteur du facteur de liberation de la corticotropine (crf)
NZ554082A NZ554082A (en) 2004-10-19 2005-10-19 Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
AU2005295353A AU2005295353B2 (en) 2004-10-19 2005-10-19 Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
BRPI0517073-7A BRPI0517073A (pt) 2004-10-19 2005-10-19 derivados pirazolo [1,5-alfa] pirimidinil úteis como antagonistas do receptor do fator de liberação de corticotropina (crf)
MX2007004701A MX2007004701A (es) 2004-10-19 2005-10-19 Derivados de pirazolo [1,5-alfa] pirimidinilo utiles como antagonistas del receptor al factor liberador de corticotropina.
JP2007537996A JP4901744B2 (ja) 2004-10-19 2005-10-19 副腎皮質刺激ホルモン放出因子（ｃｒｆ）受容体アンタゴニストとして有用なピラゾロ［１，５−アルファ］ピリミジニル誘導体
EP05818308A EP1802627B1 (fr) 2004-10-19 2005-10-19 Derives de pyrazolo (1,5-alpha) pyrimidinyle utiles comme antagonistes vis-a-vis du recepteur du facteur de liberation de la corticotropine (crf)
US11/576,957 US7879862B2 (en) 2004-10-19 2005-10-19 Pyrazolo[1,5-alpha]pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
PE2006001185A PE20070845A1 (es) 2005-09-30 2006-09-28 Derivados de pirazolo[1,5-alfa]pirimidin utiles como receptores antagonistas del factor de liberacion de corticotropina (crf)
TW095135886A TW200745121A (en) 2005-09-30 2006-09-28 Chemical compound
EP06805979A EP1934222B1 (fr) 2005-09-30 2006-09-28 Composés de type pyrazolo[1, 5-alpha]pyrimidinyle pouvant être employés en tant qu'antagonistes du récepteur du facteur de libération de la corticotropine (CRF)
EA200801000A EA200801000A1 (ru) 2005-09-30 2006-09-28 Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf)
AU2006298995A AU2006298995B2 (en) 2005-09-30 2006-09-28 Pyrazolo [1, 5 -alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
KR1020087007620A KR20080063760A (ko) 2005-09-30 2006-09-28 코르티코트로핀-방출 인자 (ｃｒｆ) 수용체 길항제로서유용한 피라졸로[1,5-알파]피리미디닐 유도체
JP2008532687A JP2009510004A (ja) 2005-09-30 2006-09-28 コルチコトロピン放出因子（ＣＲＦ）受容体拮抗薬として有用なピラゾロ［１，５−α］ピリミジニル誘導体
CN2006800355977A CN101273043B (zh) 2005-09-30 2006-09-28 用作促肾上腺皮质激素释放因子（CRF）受体拮抗剂的吡唑并[1,5-a]嘧啶基衍生物
CA002624699A CA2624699A1 (fr) 2005-09-30 2006-09-28 Composes de type pyrazolo[1,5-alpha]pyrimidinyle pouvant etre employes en tant qu'antagonistes du recepteur du facteur de liberation de la corticotropine (crf)
PCT/EP2006/009531 WO2007039264A1 (fr) 2005-09-30 2006-09-28 Composés de type pyrazolo[1,5-alpha]pyrimidinyle pouvant être employés en tant qu'antagonistes du récepteur du facteur de libération de la corticotropine (crf)
US12/067,939 US8088779B2 (en) 2005-09-30 2006-09-28 Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
BRPI0616767-5A BRPI0616767A2 (pt) 2005-09-30 2006-09-28 derivados de pirazolo [1,5-alfa]pirimidinila úteis como antagonistas de receptores de fatores de liberação de corticotropina (crf), composição contendo tais compostos, bem como usos
IL182420A IL182420A0 (en) 2004-10-19 2007-04-10 Crf receptor antagonists and methods relating thereto
NO20072541A NO20072541L (no) 2004-10-19 2007-05-16 Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster
IL190225A IL190225A0 (en) 2005-09-30 2008-03-17 Pyrazolo [1,5-alpha]pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists
MA30813A MA29850B1 (fr) 2005-09-30 2008-04-04 Composes de type pyrazolo [1.5 -alpha] pyrimidinyle pouvant etre employes en tant qu'antagonistes du recepteur du facteur de liberation de la corticotropine (crf)
NO20081941A NO20081941L (no) 2005-09-30 2008-04-23 Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62006004P 2004-10-19 2004-10-19
US60/620,060 2004-10-19
GBGB0519957.5A GB0519957D0 (en) 2005-09-30 2005-09-30 Chemical compound
GB0519957.5 2005-09-30

Publications (2)

Publication Number Publication Date
WO2006044958A1 WO2006044958A1 (fr) 2006-04-27
WO2006044958A8 true WO2006044958A8 (fr) 2006-06-08

Family

ID=35395069

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/037576 WO2006044958A1 (fr) 2004-10-19 2005-10-19 Derives de pyrazolo[1,5-alpha]pyrimidinyle utiles comme antagonistes vis-a-vis du recepteur du facteur de liberation de la corticotropine (crf)
PCT/EP2006/009531 WO2007039264A1 (fr) 2005-09-30 2006-09-28 Composés de type pyrazolo[1,5-alpha]pyrimidinyle pouvant être employés en tant qu'antagonistes du récepteur du facteur de libération de la corticotropine (crf)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009531 WO2007039264A1 (fr) 2005-09-30 2006-09-28 Composés de type pyrazolo[1,5-alpha]pyrimidinyle pouvant être employés en tant qu'antagonistes du récepteur du facteur de libération de la corticotropine (crf)

Country Status (21)

Country Link
US (1) US7879862B2 (fr)
EP (2) EP1802627B1 (fr)
JP (2) JP4901744B2 (fr)
KR (2) KR20070088621A (fr)
CN (1) CN101273043B (fr)
AR (2) AR051461A1 (fr)
AU (2) AU2005295353B2 (fr)
BR (1) BRPI0616767A2 (fr)
CA (2) CA2584567C (fr)
CR (1) CR9918A (fr)
EA (1) EA200801000A1 (fr)
GB (1) GB0519957D0 (fr)
IL (1) IL190225A0 (fr)
MA (1) MA29850B1 (fr)
NO (2) NO20072541L (fr)
NZ (1) NZ554082A (fr)
PE (2) PE20060586A1 (fr)
RU (1) RU2007118683A (fr)
TW (2) TW200626599A (fr)
UA (1) UA92756C2 (fr)
WO (2) WO2006044958A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ547990A (en) * 2003-12-22 2010-04-30 Smithkline Beecham Cork Ltd CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en) 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009085913A1 (fr) 2007-12-19 2009-07-09 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines utiles en tant qu'inhibiteurs de jak2
MY152687A (en) * 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2487177A1 (fr) * 2009-10-08 2012-08-15 Eisai R&D Management Co., Ltd. Composé de pyrazolooxazole
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102753527B (zh) * 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
US20140309226A1 (en) 2011-11-16 2014-10-16 Array Biopharma Inc. Piperidinyl-substituted cyclic ureas as gpr119 modulators
EP2841068B8 (fr) * 2012-04-23 2019-03-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antagonistes de crhr1 pour une utilisation dans le traitement de patients présentant une hyperactivité de la crh
BR112014026210A2 (pt) 2012-05-03 2017-06-27 Novartis Ag derivados de sal l-malato de 2,7-diaza-espiro[4.5]dec-7-il e formas cristalinas dos mesmos como agonistas do receptor de grelina
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
BR112016016975B1 (pt) 2014-01-21 2022-12-27 Neurocrine Biosciences Inc Usos de um antagonista do receptor crf1 para o tratamento de hiperplasia adrenal congênita e para reduzir níveis de 17-ohp e acth em um paciente
AU2015208205B2 (en) * 2014-01-22 2019-12-05 Curovir Ab Pyrazolo[1,5-a]pyrimidines as antiviral compounds
AU2018221705B2 (en) 2017-02-17 2022-10-27 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CA3165424A1 (fr) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Oxadiazoles fluoroalkyles et leurs utilisations
JP2023546729A (ja) * 2020-10-27 2023-11-07 トレベナ・インコーポレイテッド デルタオピオイドモジュレーターの結晶形及び非晶形

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
AU680370B2 (en) 1994-06-21 1997-07-24 Otsuka Pharmaceutical Factory, Inc. Pyrazolo(1,5-a)pyrimidine derivative
WO1997029109A1 (fr) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines en tant qu'antagonistes du recepteur de crf
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
BR9710544A (pt) * 1996-07-24 1999-08-17 Du Pont Pharm Co M-todo de tratamento composto e composi-Æo farmac-utica
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
WO1998003510A1 (fr) 1996-07-24 1998-01-29 Du Pont Pharmaceuticals Company Azolo triazines et pyrimidines
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
BR9711970A (pt) 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
SI1049699T1 (en) 1998-01-28 2004-10-31 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as crf antagonists
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
EP1149835A4 (fr) 1999-01-29 2002-08-21 Sumitomo Chemical Co Agents inhibiteurs d'accumulation de graisse
WO2000059908A2 (fr) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines antagonistes de corticoliberine (crf)
CN1377355A (zh) 1999-09-30 2002-10-30 纽罗杰有限公司 氨基取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
WO2001023387A2 (fr) 1999-09-30 2001-04-05 Neurogen Corporation PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES A SUBSTITUTION ALKYLENE-DIAMINE ET PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
IL158062A0 (en) 2001-04-30 2004-03-28 Glaxo Group Ltd Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
ES2307750T3 (es) 2001-06-12 2008-12-01 Glaxo Group Limited Antagonistas del factor de liberacion de corticotropina.
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
DE60319820T2 (de) 2002-06-04 2009-03-26 Schering Corp. Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
DE602004005960T2 (de) 2003-01-16 2008-01-17 Sb Pharmco Puerto Rico Inc. Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
EP1608652A1 (fr) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Composes pyrazolopyrimidines et leur utilisation en medecine
US20070021429A1 (en) 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
JP2007515474A (ja) 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
NZ547990A (en) 2003-12-22 2010-04-30 Smithkline Beecham Cork Ltd CRF receptor antagonists and methods relating thereto
DE102004008807A1 (de) 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
EP1802621B1 (fr) 2004-10-19 2009-05-06 SmithKline Beecham (Cork) Limited Antagonistes du recepteur du crf et procedes associes
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
WO2007039264A1 (fr) 2007-04-12
CA2584567C (fr) 2013-04-30
NO20081941L (no) 2008-04-23
CN101273043B (zh) 2011-08-03
NZ554082A (en) 2010-12-24
TW200745121A (en) 2007-12-16
US20080194589A1 (en) 2008-08-14
JP2008517067A (ja) 2008-05-22
BRPI0616767A2 (pt) 2011-06-28
US7879862B2 (en) 2011-02-01
MA29850B1 (fr) 2008-10-03
GB0519957D0 (en) 2005-11-09
NO20072541L (no) 2007-06-25
EP1934222B1 (fr) 2012-07-25
AU2005295353B2 (en) 2012-01-12
CR9918A (es) 2009-02-03
EP1802627A1 (fr) 2007-07-04
PE20060586A1 (es) 2006-09-20
JP2009510004A (ja) 2009-03-12
CA2584567A1 (fr) 2006-04-27
AR051461A1 (es) 2007-01-17
CA2624699A1 (fr) 2007-04-12
WO2006044958A1 (fr) 2006-04-27
RU2007118683A (ru) 2008-11-27
AU2006298995A1 (en) 2007-04-12
AU2006298995B2 (en) 2012-06-14
AR056104A1 (es) 2007-09-19
UA92756C2 (ru) 2010-12-10
JP4901744B2 (ja) 2012-03-21
KR20070088621A (ko) 2007-08-29
TW200626599A (en) 2006-08-01
EP1802627B1 (fr) 2012-08-29
EA200801000A1 (ru) 2009-02-27
CN101273043A (zh) 2008-09-24
PE20070845A1 (es) 2007-08-25
KR20080063760A (ko) 2008-07-07
EP1934222A1 (fr) 2008-06-25
AU2005295353A1 (en) 2006-04-27
IL190225A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
WO2006044958A8 (fr) Derives de pyrazolo[1,5-alpha]pyrimidinyle utiles comme antagonistes vis-a-vis du recepteur du facteur de liberation de la corticotropine (crf)
WO2006044821A8 (fr) Antagonistes du recepteur du crf et procedes associes
TW200635930A (en) Bicyclic pyrrole derivatives
JO2783B1 (en) Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
DK1646389T3 (da) Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister
WO2006069805A3 (fr) Pyrido(3,2-d)pyrimidines et compositions pharmaceutiques utiles en therapie medicale
WO2006084017A3 (fr) Composes pyrimidine a substitution phenyle utilises en tant qu'inhibiteurs de kinases
WO2000027846A3 (fr) Antagonistes de recepteurs du crf et methodes associees
WO2006033795A3 (fr) Methode d'utilisation de pyrazolo [1,5-a] pyrimidines substituees
MXPA06000300A (es) Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de gonadotropina.
WO2003022219A3 (fr) Derives de purine biaryle a substitution azote utiles en tant que puissants agents antiproliferatifs
WO2003068776A1 (fr) Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
EP1988075A4 (fr) Dérivé de pyrrole ou sel de celui-ci
DE60215637D1 (de) Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
UA93522C2 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones
TW200634022A (en) Difluoronucleosides and process for preparation thereof
MX2007004701A (es) Derivados de pirazolo [1,5-alfa] pirimidinilo utiles como antagonistas del receptor al factor liberador de corticotropina.
AU2001261850A1 (en) Crf receptor antagonists and methods relating thereto
AU2001263329A1 (en) Crf receptor antagonists and methods relating thereto
MXPA05010633A (es) Compuestos de pirrolo(1,2-b)piridazina y su uso como antagonistas del receptor de factor liberador de corticotropina-1.
DE602004012318D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
MXPA05010833A (es) Compuestos de pirrolo[1,2-b]piridazina y sus usos.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 17/2006 ADD "DECLARATION UNDER RULE 4.17: - AS TO APPLICANT'S ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT (RULE 4.17(II))."; ADD "DECLARATION UNDER RULE 4.17: - AS TO THE APPLICANT'S ENTITLEMENT TO CLAIM THE PRIORITY OF THE EARLIER APPLICATION (RULE 4.17(III)) FOR ALL DESIGNATIONS."; ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 554082

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007/02467

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005295353

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12007500716

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 11576957

Country of ref document: US

Ref document number: 182420

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2733/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005818308

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2584567

Country of ref document: CA

Ref document number: MX/a/2007/004701

Country of ref document: MX

Ref document number: 1020077008794

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005295353

Country of ref document: AU

Date of ref document: 20051019

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007537996

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2005295353

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2007000296

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1200701017

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2007118683

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580043716.9

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005818308

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008030514

Country of ref document: EG

ENP Entry into the national phase

Ref document number: PI0517073

Country of ref document: BR